Whole-body Vibration Training,Whole-Body Vibration With Regional Plantar Stimulation,Baduanjin: Participants will complete three types of intervention conditions. In the whole-body vibration condition, participants will stand barefoot on a vibration platform with feet about 20 cm apart and knees flexed at 20°-25°. Vibration will be delivered at 20 Hz and 2 mm for 60 seconds. In the whole-body vibration with regional plantar stimulation condition, the same vibration parameters and posture will be used, while a plantar stimulation module is placed on the platform. Four plantar regions will be stimulated separately: the toe region, metatarsal head region, medial plantar region, and lateral plantar region. In the Baduanjin condition, participants will perform a heel-raise movement derived from Baduanjin under professional guidance, completing six repetitions within 60 seconds.
This study will examine how different short-term exercise and vibration conditions affect lower-limb muscle activity in young adults with flat feet and young adults with normal feet.
Participants will complete several conditions, including whole-body vibration, whole-body vibration combined with plantar stimulation under different areas of the foot, and a Baduanjin heel-raise exercise. Surface electromyography sensors will be placed on the skin over selected lower-limb muscles to record muscle activity before and during each condition. Each participant will complete all study conditions in a balanced order.
This study does not aim to treat flat feet or evaluate long-term clinical benefits. The purpose is to collect preliminary information on immediate muscle activation and foot discomfort, which may help design future studies on foot-related exercise, plantar stimulation, and rehabilitation training.
| Facility | City | Region | Status |
|---|---|---|---|
| Nanfang Hospital, Southern Medical University | Guangzhou | Guangdong | Recruiting |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07811674 on ClinicalTrials.gov ↗ ← All trials in China